GRAILGRAL -0.92%12 OCF Margin % is -213.29% as of Mar. 2026. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, GRAIL ranks worse than 84.31% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. GRAIL's Cash Flow from Operations for the
three
months ended in Mar. 2026 was $-87.0 Mil. GRAIL's Revenue for the
three
months ended in Mar. 2026 was $40.8 Mil. Therefore, GRAIL's OCF Margin % for the quarter that ended in Mar. 2026 was -213.29%.
The historical rank and industry rank for GRAIL's OCF Margin % or its related term are showing as below:
GRAL'
s OCF Margin % Range Over the Past 10 Years
Min: -1010.46 Med: -549.73 Max: -203.17
Current: -186.38
During the past 6 years, the highest OCF Margin % of GRAIL was -203.17%. The lowest was -1010.46%. And the median was -549.73%.
GRAL's OCF Margin % is ranked worse than 84.31% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs GRAL: -186.38
GRAIL OCF Margin % Related Terms
GRAIL OCF Margin % Historical Data
* Premium members only.
The historical data trend for GRAIL's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GRAIL's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's OCF Margin % distribution charts can be found below:
* The bar in red indicates where GRAIL's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRAIL (GRAL) has a OCF Margin % of -213.29% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GRAIL and its competitors. According to the industry distribution chart, GRAIL ranks #172 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 84.3%.
Is GRAIL's OCF Margin % too high?
GRAIL's current OCF Margin % is -213.29%. Based on the distribution chart, GRAIL ranks #172 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's OCF Margin % compare to VCYT and ADPT?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #172 out of 204 companies for OCF Margin %. This places GRAIL in the lower half of its industry. The industry median OCF Margin % is 4.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current OCF Margin % is -213.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current OCF Margin % of -213.29%. The current OCF Margin % is -213.29%. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For GRAIL (GRAL), the current OCF Margin % is -213.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score
Get the complete analysis for GRAL
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
